Nearly 1 in 3 patients with inflammatory bowel disease receive biologic agents or JAK inhibitors within 5 years of diagnosis, and their use is linked to a lower risk for hospitalisations.
Everyday Health on MSN
5 things to know about the IBD-IBS overlap
Inflammatory bowel disease and irritable bowel syndrome often occur together. Find out what you need to be aware of when you ...
Most women with IBD who undergo fertility treatment achieve pregnancy, and success does not appear to vary with active ...
Investor's Business Daily on MSN
IBD stock of the day, Natera, hovering near buy point
Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.
Analysts say that duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up.
Antibody patterns in the blood may help doctors identify people at risk so they can be treated earlier, research shows ...
While relatively uncommon, UC that starts in childhood tends to be more extensive and severe than when it emerges in ...
It can be helpful to keep tabs on symptoms, triggers, and other data to help manage inflammatory bowel disease. Find out what ...
Teva Pharmaceutical Industries Ltd. ( TEVA) and Sanofi ( SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (UC) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results